Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
Executive Summary
John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines